Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: Have they impacted the National Health Service budget?

Health Policy

Volumn 110, Issue 1, 2013, Pages 49-59

  Mauskopf, Josephine ^a   Chirila, Costel ^a   Birt, Julie ^b   Boye, Kristina S ^b   Bowman, Lee ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Budget impact; England; Financial impact; NICE; Reimbursement; Wales

Indexed keywords

ARTICLE; BUDGET; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; DRUG INDICATION; DRUG MARKETING; HEALTH CARE ORGANIZATION; HUMAN; NATIONAL HEALTH SERVICE; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; POTENTIAL BUDGET IMPACT; REIMBURSEMENT; UNITED KINGDOM;

BUDGETS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS; STATE MEDICINE; TREATMENT OUTCOME;

EID: 84875232517     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.01.017     Document Type: Article

References (10)

1. National Institute for Health and Clinical Excellence How guidance topics are chosen 2011, http://www.nice.org.uk/aboutnice/howwework/howguidancetopicsarechosen/how_guidance_topics_are_chosen.jsp.
2. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal June 2008, http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
3. National Institute for Health and Clinical Excellence (NICE) Single technology appraisal. Specification for manufacturer/sponsor submission of evidence (draft) December 2008, http://www.nice.org.uk/media/E29/DF/SpecificationForManufacturerSponsorSubmissionofEvidenceDraft.pdf.
4. Clement F.M., Harris A., Li J.J., Yong K., Lee K.M., Manns B.J. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. Journal of the American Medical Association 2009, 302:1437-1443.
5. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004, 13:437-452.
6. Dakin H.A., Devlin N.J., Odeyemi I.A.O. " Yes" , " No" or " Yes, but" ? Multinomial modelling of NICE decision-making. Health Policy 2006, 77:352-367.
7. Chim L., Kelly P.J., Salkeld G., Stockler M.R. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?. Pharmacoeconomics 2010, 28:463-475.
8. Harris A.H., Hill S.R., Chin G., Li J.J., Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Medical Decision Making 2008, 28:713-722.
9. Mauskopf J., Chirila C., Masaquel C., Boye K.S., Bowman L., Birt J., et al. The relationship between financial impact and the likelihood of drug reimbursement in the Australian health care system. Value Health 2011, 14:A22.
10. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, John Wiley & Sons, Hoboken, NJ. 2nd ed.